Clinical trials · Illinois
Leukemia clinical trials in Illinois
We’re tracking 98 recruiting leukemia studies with a site in Illinois — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
Chicago, IllinoisAges 1 year+ - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Chicago, IllinoisAges 12 years+ - NCT05082519RecruitingPhase 2
Calorie restriction and exercise to improve leukemia treatment in young patients
This study tests whether a special diet (calorie restriction) and increased physical activity can make chemotherapy work better for young people with B-ALL. Participants will follow a monitored diet and exercise plan during their first month of treatment.
Chicago, IllinoisAges 7–25 - NCT07342478RecruitingPhase 3
Comparing two BTK inhibitors for CLL/SLL after prior treatment
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Skokie, IllinoisAges 18 years+ - NCT07756034Recruiting
Cancer data registry for patients in the U.S.
This study collects information from people with cancer to help researchers learn more about the disease. You may join a general cancer registry or, if your child has a specific type of leukemia, a special part of the study.
Chicago, IllinoisAges Any age - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Chicago, IllinoisAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Chicago, IllinoisAges 18 years+ - NCT04187105RecruitingPhase 2
Total marrow radiation using a targeted intensity plan before transplant
This Phase 2 study tests a more precise type of whole bone-marrow radiation before a stem cell transplant. It may help patients with certain high-risk blood cancers by preparing the body for transplant more safely and effectively.
Chicago, IllinoisAges 18–75 - NCT03326310RecruitingPhase 1
Selumetinib plus azacitidine for high-risk blood cancers
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Chicago, IllinoisAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chicago, IllinoisAges Any age - NCT04293562RecruitingPhase 3
Testing targeted drugs plus chemo for newly diagnosed AML
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Chicago, IllinoisAges Up to 21 years - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Chicago, IllinoisAges 18 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Chicago, IllinoisAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Chicago, IllinoisAges 18 years+ - NCT05289687RecruitingPhase 2
Daratumumab for hard-to-clear T-cell leukemia traces
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
Chicago, IllinoisAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Chicago, IllinoisAges 18 years+ - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Chicago, IllinoisAges Up to 26 years - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Chicago, IllinoisAges 18 years+ - NCT06714591RecruitingPhase 1
Testing BL-M11D1 for advanced AML
This trial tests a new drug called BL-M11D1 for people with a type of leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and works against cancer cells that have a protein called CD33.
Chicago, IllinoisAges 18 years+ - NCT06876662RecruitingPhase 4
Continuing pirtobrutinib for CLL and lymphoma patients
This trial continues to give pirtobrutinib to people with chronic lymphocytic leukemia or certain other lymphomas who were already in a previous study with this drug. It helps researchers keep track of long-term safety and how well the drug works over time.
Chicago, IllinoisAges 18 years+ - NCT06876649RecruitingPhase 4
Long-term safety study of Pirtobrutinib
This trial is for people who are already in a Lilly study taking pirtobrutinib. It looks at the long-term safety of the drug by continuing to monitor you.
Chicago, IllinoisAges 18 years+ - NCT06960993Recruiting
Mosaic trial for stem cell transplant patients
This trial tests a website designed to help patients learn about stem cell transplants for blood cancers. It aims to support you during your transplant journey.
Chicago, IllinoisAges 18 years+ - NCT07294677RecruitingPhase 1/Phase 2
Study of capivasertib, venetoclax, and low-intensity chemo for ALL/LBL
This trial tests a combination of targeted drugs (capivasertib and venetoclax) with a gentle form of chemotherapy for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or has not responded to previous treatment. The goal is to see if this approach is safe and effective.
Chicago, IllinoisAges 18 years+ - NCT01804686RecruitingPhase 3
Long-term ibrutinib follow-up with or without nivolumab
This study looks at how safe and effective ibrutinib is over the long term, either alone or together with nivolumab. You may join if you are already in an earlier ibrutinib study and your care team feels staying on ibrutinib is worth the risk.
Chicago, IllinoisAges 18 years+
Leukemia trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting leukemia studies listed above.
- Northwestern University · 6 studies
- University of Chicago · 6 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago · 3 studies
- Northwestern Memorial Hospital · 2 studies
- University of Illinois · 2 studies
- Advocate Children's Hospital - Oak Lawn
- Advocate Children's Hospital - Park Ridge
- Illinois Cancer Specialists
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Leukemia trials in other states
Common questions
- Are there leukemia clinical trials in Illinois?
- Yes. We're currently tracking 98 recruiting leukemia studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.